Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Treatment of walking impairment in multiple sclerosis with dalfampridine.
Serological evidence of increased susceptibility to varicella-zoster virus reactivation or reinfection in natalizumab-treated patients with multiple sclerosis.
Microvesicles: novel biomarkers for neurological disorders.
Narcolepsy with cataplexy and comorbid immunopathological diseases.
The risk of varicella zoster virus infection in multiple sclerosis patients treated with fingolimod.
Atypical guillain-barré syndrome misdiagnosed as lumbar spinal stenosis.
Amiloride Clinical Trial In Optic Neuritis (ACTION) protocol: a randomised, double blind, placebo controlled trial.
Review of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosis.
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.
Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica.
Use of the multiple sclerosis functional composite as an outcome measure in a phase 3 clinical trial.
Tumefactive multiple sclerosis lesions under fingolimod treatment.
CHMP assessment report for Sovrima (International nonproprietary name: idebenone)
Unusual case of gastroparesis leading to severe gastromegaly with demyelinating disease as a rare cause.
Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis.
A Network Meta-Analysis of Efficacy and Evaluation of Safety of Subcutaneous Pegylated Interferon Beta-1a versus Other Injectable Therapies for the Treatment of Relapsing-Remitting Multiple Sclerosis.
Exogenous schwann cells migrate, remyelinate and promote clinical recovery in experimental auto-immune encephalomyelitis.
The potential role of epigenetic modifications in the heritability of multiple sclerosis.
Confounding in association studies: month of birth and multiple sclerosis.
Treatment selection and experience in multiple sclerosis: survey of neurologists.
Synthon announces successful outcome of the Phase III GATE study with its generic glatiramer acetate
Phenytoin (Dilantin) and acupuncture therapy in the treatment of intractable oral and facial pain.
Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1-images in multiple sclerosis.
Eicosapentaenoic acid (EPA) induces peroxisome proliferator-activated receptors and ameliorates experimental autoimmune encephalomyelitis.

Pages